Bristol Myers Squibb (CELG-RI) EBT Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) EBT Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.28% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.91% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 49.60% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 16.87% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 10.26% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 19.70% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -103.74% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -31.77% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -42.41% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 30.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.02% |
| Mar 31, 2026 | 5.36% |
| Dec 31, 2025 | -7.53% |
| Sep 30, 2025 | 12.13% |
| Jun 30, 2025 | -3.25% |
| Mar 31, 2025 | 20.76% |
| Dec 31, 2024 | -54.50% |
| Sep 30, 2024 | -8.07% |
| Jun 30, 2024 | -6.09% |
| Mar 31, 2024 | -87.12% |
| Dec 31, 2023 | 29.27% |
| Sep 30, 2023 | -1.80% |
| Jun 30, 2023 | 4.54% |
| Mar 31, 2023 | 123.15% |
| Dec 31, 2022 | 154.12% |
| Sep 30, 2022 | 17.87% |
| Jun 30, 2022 | 3.31% |
| Mar 31, 2022 | -5.18% |
| Dec 31, 2021 | 7.28% |
| Sep 30, 2021 | -0.15% |